These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35626057)

  • 21. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
    Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells.
    Gatto F; Arvigo M; Amarù J; Campana C; Cocchiara F; Graziani G; Bruzzone E; Giusti M; Boschetti M; Ferone D
    Pituitary; 2019 Feb; 22(1):89-99. PubMed ID: 30483918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. USP8 Mutations and Cell Cycle Regulation in Corticotroph Adenomas.
    Martins CS; Camargo RC; Coeli-Lacchini FB; Saggioro FP; Moreira AC; de Castro M
    Horm Metab Res; 2020 Feb; 52(2):117-123. PubMed ID: 32053843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas.
    Losa M; Mortini P; Pagnano A; Detomas M; Cassarino MF; Pecori Giraldi F
    Endocrine; 2019 Feb; 63(2):240-246. PubMed ID: 30315484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors.
    Castellnou S; Vasiljevic A; Lapras V; Raverot V; Alix E; Borson-Chazot F; Jouanneau E; Raverot G; Lasolle H
    Endocr Connect; 2020 Feb; 9(3):243-53. PubMed ID: 32101529
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation.
    Kageyama K; Asari Y; Sugimoto Y; Niioka K; Daimon M
    Endocr J; 2020 Feb; 67(2):177-184. PubMed ID: 31666445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
    Iacovazzo D; Carlsen E; Lugli F; Chiloiro S; Piacentini S; Bianchi A; Giampietro A; Mormando M; Clear AJ; Doglietto F; Anile C; Maira G; Lauriola L; Rindi G; Roncaroli F; Pontecorvi A; Korbonits M; De Marinis L
    Eur J Endocrinol; 2016 Feb; 174(2):241-50. PubMed ID: 26586796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatic USP8 Gene Mutations Are a Common Cause of Pediatric Cushing Disease.
    Faucz FR; Tirosh A; Tatsi C; Berthon A; Hernández-Ramírez LC; Settas N; Angelousi A; Correa R; Papadakis GZ; Chittiboina P; Quezado M; Pankratz N; Lane J; Dimopoulos A; Mills JL; Lodish M; Stratakis CA
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2836-2843. PubMed ID: 28505279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Responsiveness to DDAVP in Cushing's disease is associated with USP8 mutations through enhancing AVPR1B promoter activity.
    Shichi H; Fukuoka H; Kanzawa M; Yamamoto M; Yamamoto N; Suzuki M; Urai S; Matsumoto R; Kanie K; Fujita Y; Bando H; Iguchi G; Inoshita N; Yamada S; Takahashi Y; Ogawa W
    Pituitary; 2022 Jun; 25(3):496-507. PubMed ID: 35451730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. USP8 mutations in corticotroph adenomas determine a distinct gene expression profile irrespective of functional tumour status.
    Bujko M; Kober P; Boresowicz J; Rusetska N; Paziewska A; Dąbrowska M; Piaścik A; Pękul M; Zieliński G; Kunicki J; Bonicki W; Ostrowski J; Siedlecki JA; Maksymowicz M
    Eur J Endocrinol; 2019 Dec; 181(6):615-627. PubMed ID: 31581124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing's Disease.
    Shen Y; Ji C; Jian X; Zhou J; Zhang Q; Qiao N; Zhang Y; Shou X; Zhou X; Ma Z
    Front Endocrinol (Lausanne); 2020; 11():601984. PubMed ID: 33537004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activity in male rat anterior pituitary.
    Nolan LA; Schmid HA; Levy A
    Endocrinology; 2007 Jun; 148(6):2821-7. PubMed ID: 17347306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
    van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant.
    Pivonello R; Munster PN; Terzolo M; Ferrigno R; Simeoli C; Puglisi S; Bali U; Moraitis AG
    Front Endocrinol (Lausanne); 2021; 12():793262. PubMed ID: 35058882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Novel Mechanism Regulating Dopamine Receptor Type 2 Signal Transduction in Pituitary Tumoral Cells: The Role of cAMP/PKA-Induced Filamin A Phosphorylation.
    Mangili F; Treppiedi D; Catalano R; Marra G; Di Muro G; Spada A; Arosio M; Peverelli E; Mantovani G
    Front Endocrinol (Lausanne); 2020; 11():611752. PubMed ID: 33664708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. USP8, USP48, and BRAF mutations differ in their genotype-phenotype correlation in Asian Indian patients with Cushing's disease.
    Abraham AP; Pai R; Beno DL; Chacko G; Asha HS; Rajaratnam S; Kapoor N; Thomas N; Chacko AG
    Endocrine; 2022 Feb; 75(2):549-559. PubMed ID: 34664215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paradoxical and atypical responses to pasireotide in aggressive ACTH-secreting pituitary tumors.
    Greenman Y; Stern N
    Pituitary; 2016 Dec; 19(6):605-611. PubMed ID: 27639583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential microRNA Expression in
    Bujko M; Kober P; Boresowicz J; Rusetska N; Zeber-Lubecka N; Paziewska A; Pekul M; Zielinski G; Styk A; Kunicki J; Ostrowski J; Siedlecki JA; Maksymowicz M
    J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33498176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.
    Asari Y; Kageyama K; Sugiyama A; Kogawa H; Niioka K; Daimon M
    Endocr J; 2019 Jun; 66(6):515-522. PubMed ID: 30880293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST
    Pedraza-Arevalo S; Ibáñez-Costa A; Blázquez-Encinas R; Branco MR; Vázquez-Borrego MC; Herrera-Martínez AD; Venegas-Moreno E; Serrano-Blanch R; Arjona-Sánchez Á; Gálvez-Moreno MA; Korbonits M; Soto-Moreno A; Gahete MD; Charalambous M; Luque RM; Castaño JP
    Mol Oncol; 2022 Feb; 16(3):764-779. PubMed ID: 34601790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.